A: The key ingredients are Glutathione and Vitamin C, known for their antioxidant and skin-enhancing properties
Sixty-nine males (50%) and seventy females (50%), with a median age of 56 years (range 2689 years), were recruited
In part one, we talked about the misleading claim of a 20% reduction in Major Adverse Cardiac Events that appeared in a Novo company announcement. Now lets look at the second two parts of their claim: that the risk reduction (which, spoiler alert, is actually 1.5% not 20%) was in Adults with overw*ight and ob*sity As I wrote in the previous piece, their trial criteria only included people aged 45 and older, with existing cardiovascular disease and without type 2 diabetes with a BMI of 27 or higher (while BMI is worse-than-useless measurement with a racist basis, since they are using it, I want to point out that the actual definition of overw*ight starts at a BMI over 25 not 27.) Still, the study itself shows their use of adults to be even more misleading than it originally appeared
:max_bytes(150000):strip_icc()/GettyImages-2126120280-94c8334d07474c6883f6bb568b95693f.jpg)
The study also showed that people who received Ozempic experienced slower rates of decline in kidney function, were 20% less likely to die from any cause, and were also 18% less likely to experience major adverse cardiac events (MACE)
Before starting treatment, tell your doctor if you have ever had an allergic reaction to semaglutide, other weight loss medications, or any other drugs